Literature DB >> 6142370

Visual loss in patient on high-dose subcutaneous desferrioxamine.

C Borgna-Pignatti, P De Stefano, A M Broglia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6142370     DOI： 10.1016/s0140-6736(84)92195-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

2.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 3.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.

Authors:  E A Llados i Vallory; R Girot; G Lenoir; M Payet; P Houze; R Bourdon
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.